Table 2.
Treatment profiles of the subjects.
| Total | IL-12B rs6871626 | LILRA3 rs103294 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CC | AC | AA | p value | CC | CT | TT | p value | ||
| Number | 19 | 53 | 27 | 1 | 38 | 60 | |||
| Medication | |||||||||
| Glucocorticoid | 79 (80%) | 15 (79%) | 42 (79%) | 22 (81%) | 0.82 | 1 (100%) | 30 (79%) | 48 (80%) | 0.97 |
| Oral immunosuppressant | 38 (39%) | 5 (26%) | 22 (42%) | 11 (41%) | 0.38 | 1 (100%) | 14 (38%) | 23 (38%) | 0.72 |
| Biologic | 17 (17%) | 1 (5%) | 10 (19%) | 6 (22%) | 0.15 | 1 (100%) | 6 (16%) | 10 (17%) | 0.52 |
| Surgery or catheterization | 34 (35%) | 8 (42%) | 12 (23%) | 14 (52%) | 0.31 | 0 (0%) | 11 (30%) | 23 (38%) | 0.29 |
| CABG | 5 (5%) | 2 (11%) | 3 (6%) | 0 (0%) | 0.1 | 0 (0%) | 1 (3%) | 4 (7%) | 0.35 |
| PCI | 7 (7%) | 2 (11%) | 4 (8%) | 1 (4%) | 0.37 | 0 (0%) | 1 (3%) | 6 (10%) | 0.14 |
| Aortic valve replacement | 9 (9%) | 1 (5%) | 2 (4%) | 6 (22%) | 0.023* | 0 (0%) | 4 (11%) | 5 (8%) | 0.78 |
| Aneurysm repair | 10 (10%) | 2 (11%) | 2 (4%) | 6 (22%) | 0.11 | 0 (0%) | 6 (16%) | 4 (7%) | 0.2 |
| Bypass surgery | 9 (9%) | 2 (11%) | 3 (6%) | 4 (15%) | 0.51 | 0 (0%) | 2 (5%) | 7 (12%) | 0.26 |
CABG coronary artery bypass grafting, PCI percutaneous coronary intervention.
Data are n (%) or mean ± standard deviation.